Grass pollen allergen-specific antibodies (IgE, IgG, and IgG4)

Polyclonal IgE, IgG, and IgG4 antibodies specific for grass pollen allergen epitopes represent the humoral immune components involved in the pathogenesis and treatment of grass pollen allergy (Shamji & Durham, 2017, PMID: 28212942). In sensitized individuals, allergen-specific IgE (sIgE) binds to high-affinity receptors (FcεRI) on mast cells and basophils; subsequent exposure to grass pollen allergens, such as Phl p 1 or Phl p 5 from Timothy grass, cross-links these antibodies to trigger inflammatory mediator release (Hauser et al., 2010, PMID: 20620152). Allergen-specific IgG4 (sIgG4) acts as a "blocking antibody" by competing with IgE for allergen epitopes and signaling through the inhibitory receptor FcγRIIb, thereby suppressing allergic inflammation (Frew, 2010, PMID: 20399414). Therapeutic strategies, particularly allergen immunotherapy (AIT), aim to shift the immune response toward the production of these protective IgG4 antibodies to induce long-term clinical tolerance (Akdis & Akdis, 2014, PMID: 24943128). Drugs such as Timothy grass pollen extracts (e.g., Grastek, Grazax) are specifically designed to modulate this antibody profile (Nelson et al., 2011, PMID: 21377491). Additionally, the monoclonal antibody omalizumab can be used to directly target and neutralize the IgE component of this system (FDA Label: Xolair). Monitoring the levels and ratios of these polyclonal antibodies serves as a critical biomarker for assessing treatment efficacy and the development of clinical tolerance in patients with allergic rhinitis or asthma.

Other names

Grass pollen-specific IgEGrass pollen-specific IgG4Timothy grass allergen antibodiesPhleum pratense specific antibodiesGrass pollen-specific immunoglobulins

Allergen immunotherapy (AIT) induces a shift from a Th2-mediated allergic response to a regulatory immune profile, characterized by the production of allergen-specific IgG4 "blocking" antibodies that compete with IgE for allergen binding and inhibit mast cell degranulation (Shamji & Durham, 2017, PMID: 28212942).